Search

Displaying results 3811 - 3820 of 7503 in total
  1. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA). … Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain.

  2. Drug

    Eperisone

    go.drugbank.com/drugs/DB08992
    Investigational

    It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.

  3. Drug

    Poloxamer 407

    go.drugbank.com/drugs/DB11252
    Investigational

    It consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene glycol blocks, both hydrophilic in nature. … Poloxamer 407 is a polyoxyethylene polymer and hydrophilic non-ionic surfactant.

  4. Drug

    Desoximetasone

    go.drugbank.com/drugs/DB00547
    Approved

    A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.

  5. Drug

    Desonide

    go.drugbank.com/drugs/DB01260
    ApprovedInvestigational

    A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.

    Mixtures: APOLAR N, DESOLEX-N
  6. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    It acts intracellularly on the MAPK signaling pathway by activating ERK2. … These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen

  7. Drug

    Tioguanine

    go.drugbank.com/drugs/DB00352
    ApprovedInvestigational

    An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

  8. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  9. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    It is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  10. Drug

    Amedalin

    go.drugbank.com/drugs/DB09188
    Experimental

    It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.